Cargando…
PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 ligands are highly expressed in some CD30+ large cell lymphomas, including classic Hodgkin lymphoma (CHL), primary mediastinal l...
Autores principales: | Xie, Wei, Medeiros, L. Jeffrey, Li, Shaoying, Tang, Guilin, Fan, Guang, Xu, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313053/ https://www.ncbi.nlm.nih.gov/pubmed/35884893 http://dx.doi.org/10.3390/biomedicines10071587 |
Ejemplares similares
-
CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases
por: Xu, Jie, et al.
Publicado: (2017) -
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018) -
Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
por: Song, Moo-Kon, et al.
Publicado: (2019) -
IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023) -
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
por: Aresu, Luca, et al.
Publicado: (2021)